BioSpace News Archive

Emerus, the nation’s first, largest and most experienced operator of small-format neighborhood hospitals in partnership with leading health systems, today announced the next step in its leadership succession plan. Craig Goguen, who has served as Chief Executive Officer (CEO) for the past five years, will become Executive Chairman.

Apotex Corp. launched the authorized generic version of Combigan® (Brimonidine Timolol OPSO 0.2%/0.5%) in the United States.

Theromics Inc., a medical device company pioneering novel technologies for interventional radiology and drug delivery, has closed a $2M seed equity financing to advance the development of HeatSYNC™, a thermal accelerant gel for optimizing and augmenting soft tissue thermal ablations.

Medical device developer Capillary Biomedical, Inc. (CapBio) has announced that it has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to start a pivotal trial for the assessment of its SteadiFlow seven-day-wear infusion set technology.

BriaCell Therapeutics Corp., is pleased to announce that all resolutions proposed to shareholders at the Annual and Special Meeting of Shareholders held virtually via teleconference on January 18, 2022 were passed.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced the publication in the New England Journal of Medicine of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection.

The concept of bioequivalence development is being highly publicized in the pharmaceutical excipients market.

HUTCHMED Limited announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor inhibitor.

Expanding center around guideline, wellbeing, and quality, development in the drug business, and passage of new parts in the market are main considerations liable for the worthwhile development of the market.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to Fact.MR, the global intravascular catheters market is predicted to grow steadily between 2021 and 2031.